Collaborations & Alliances

Janssen, Theravance Enter Pan-JAK Inhibitor Pact

To develop TD-1473, an oral, GI pan-Janus kinase (JAK) inhibitor for the treatment of inflammatory bowel disease

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The Janssen Pharmaceutical Companies of Johnson & Johnson have entered a worldwide collaboration with Theravance Biopharma to develop TD-1473, a first-in-class oral, gastrointestinal (GI) restricted pan-Janus kinase (JAK) inhibitor for the treatment of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis (UC).   Theravance will complete a Phase II study in Crohn’s disease and a Phase IIb/III study in UC, planned to start in 2018. Following Phase II ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters